Literature DB >> 6087829

Characterization of peripheral type benzodiazepine binding sites in human and rat platelets by using [3H]PK 11195. Studies in hypertensive patients.

J Benavides, D Quarteronet, P F Plouin, F Imbault, T Phan, A Uzan, C Renault, M C Dubroeucq, C Gueremy, G Le Fur.   

Abstract

Peripheral type benzodiazepine binding sites have been studied in human and rat platelets and platelet membranes by using PK 11195 (1-(2-chlorophenyl)-N-methyl-N-(1-methyl propyl)-3-isoquinolinecarboxamide) as a ligand. [3H]PK 11195 binding to the intact cells and membranes is saturable, with a high affinity and presents the pharmacological specificity corresponding to the peripheral binding sites (PK 11195 greater than RO5-4864 greater than diazepam greater than clonazepam). [3H]PK 11195 affinity is not affected by cell lysis, but there is a loss of binding capacity, contrarily to RO5-4864 whose affinity is greatly diminished. For this reason [3H]RO5-4864 binding can only be demonstrated in intact cells. Furthermore opposite to RO5-4864, PK 11195 affinity is not decreased by increasing temperatures. No difference was found between binding parameters (KD and Bmax) for [3H]PK 11195 between normotensive and hypertensive subjects. The very high binding capacity of human and rat platelets (Bmax greater than pmole/10(8) cells) makes them a good biological model for studying the physiological significance of "peripheral type" benzodiazepine binding sites.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6087829     DOI: 10.1016/0006-2952(84)90719-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Chronological study of peripheral benzodiazepine binding sites in the rat brain stab wounds using [3H] PK-11195 as a marker for gliosis.

Authors:  N Miyazawa; M Diksic; Y Yamamoto
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

2.  Synthesis and evaluation of 11C-PK 11195 for in vivo study of peripheral-type benzodiazepine receptors using positron emission tomography.

Authors:  K Hashimoto; O Inoue; K Suzuki; T Yamasaki; M Kojima
Journal:  Ann Nucl Med       Date:  1989-07       Impact factor: 2.668

3.  Reduced affinity of peripheral benzodiazepine binding sites in elderly insomniac patients.

Authors:  J C Gilbert; D Valtier; R Huguet; C Hulin; J P Aquino; P Meyer
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

4.  Effect of chronic haloperidol treatment on peripheral benzodiazepine binding sites in cerebral cortex of rats.

Authors:  M Gavish; R Weizman; D Becker; Z Tanne
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

5.  Benzodiazepine analogues inhibit arachidonate-induced aggregation and thromboxane synthesis in human platelets.

Authors:  P Fonlupt; M Croset; M Lagarde
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

6.  The 18 kDa translocator protein (peripheral benzodiazepine receptor) expression in the bone of normal, osteoprotegerin or low calcium diet treated mice.

Authors:  Winnie Wai-Ying Kam; Steven R Meikle; Hong Zhou; Yu Zheng; Julie M Blair; Marcus Seibel; Colin R Dunstan; Richard B Banati
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

7.  Specific regulation of low-abundance transcript variants encoding human Acyl-CoA binding protein (ACBP) isoforms.

Authors:  Inke Nitz; Marie-Luise Kruse; Maja Klapper; Frank Döring
Journal:  J Cell Mol Med       Date:  2011-04       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.